Jean-Pierre Bellocq
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Pierre Bellocq has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Marie-Pierre Chenard
Département de pathologie, CHU de Hautepierre, 1, avenue Molière, 67098 Strasbourg, France
7 shared publications Marie-Pierre Chenard
Department of Pathology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
6 shared publications- Carole Mathelin
Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
5 shared publications Jean-François Michiels
5 shared publicationsBruno Poulet
Institut de Pathologie de Paris, Malakoff, France
4 shared publicationsCaroline Egele
AFAQAP, hôpital de Hautepierre, Strasbourg, France
4 shared publications
Latest Publications
- 12 September 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-10
Current quality challenges in H&E preparation: The critical foundation for increased use of digital pathology and AI emergence
- 12 September 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-10
Current quality challenges in H&E preparation: The critical foundation for increased use of digital pathology and AI emergence
- 1 December 2019
- Published by Elsevier in Annales de Pathologie
- Vol. 39 (6) , 378-380
Le compte rendu augmenté comme réponse à la Grande Dépression en ACP. Impulsion, une offre de New Deal pour l’ACP
- 1 December 2019
- Published by Elsevier in Annales de Pathologie
- Vol. 39 (6) , 378-380
Le compte rendu augmenté comme réponse à la Grande Dépression en ACP. Impulsion, une offre de New Deal pour l’ACP
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e12086
Factors influencing HER2 positivity in breast cancer according to statistical modeling and data mining techniques based on a real-world national database: HER-France.
E12086 Background: HER-France is a national database collecting information on HER2 status in invasive breast cancer supplied by 124 French pathology labs (FPL). It is conducted by the French Association for Quality Control in Histopathology (AFAQAP) since October 2011. Its goal is to follow the national HER2 rate and its change over time. An analysis of this database was carried in October 2015 on 105,717 records to search for factors associated with HER2 positivity. Methods: To identify these factors, multivariate regression models were applied, as well as supervised and unsupervised Data Mining techniques such as Bayesian Networks and Decision trees were used to represent dependencies between tumor characteristics and HER2 positivity. HER2 status was determined by immunohistochemistry and in situ hybridization using ASCO/CAP 2013 guidelines. To avoid bias due to adverse pre-analytic conditions, only results on Core-Biopsies (CB) are presented hereafter. Results: Out of 105,717 records, 45,785 (43.3%) CB were analyzed. 41,586 (90.8%) CB were evaluable for HER2 status and 4,976 (12.0%) were HER2+. Factors influencing HER2 positivity were No Special Type histologic subtype (OR=2.27, 95%CI [1.89-2.77]), high histologic grade (OR=4.71, 95%CI [3.86-5.76]), negative or low hormonal receptor status (OR=1.85, 95%CI [1.67-2.04]), and higher Ki67 index (OR=3.06, 95%CI [2.72-3.44]). Bayesian Network confirmed the importance of these parameters, providing thresholds linked to high HER2 positivity rates, as shown in table below. Conclusions: HER-France is a nationwide database showing 12.0% of HER2+ on breast cancer CB between 2011 and 2015. Histological subtype, grade and ER-PR status as reported in the German database study (Ruschoff et al.), but also Ki67 are factors influencing HER2 positivity. In the future, these results should be integrated to develop new HER-France functionalities in order to allow FPL to compare their actual HER2 rate to the expected HER2 rate based on these factors.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e12086
Factors influencing HER2 positivity in breast cancer according to statistical modeling and data mining techniques based on a real-world national database: HER-France.
E12086 Background: HER-France is a national database collecting information on HER2 status in invasive breast cancer supplied by 124 French pathology labs (FPL). It is conducted by the French Association for Quality Control in Histopathology (AFAQAP) since October 2011. Its goal is to follow the national HER2 rate and its change over time. An analysis of this database was carried in October 2015 on 105,717 records to search for factors associated with HER2 positivity. Methods: To identify these factors, multivariate regression models were applied, as well as supervised and unsupervised Data Mining techniques such as Bayesian Networks and Decision trees were used to represent dependencies between tumor characteristics and HER2 positivity. HER2 status was determined by immunohistochemistry and in situ hybridization using ASCO/CAP 2013 guidelines. To avoid bias due to adverse pre-analytic conditions, only results on Core-Biopsies (CB) are presented hereafter. Results: Out of 105,717 records, 45,785 (43.3%) CB were analyzed. 41,586 (90.8%) CB were evaluable for HER2 status and 4,976 (12.0%) were HER2+. Factors influencing HER2 positivity were No Special Type histologic subtype (OR=2.27, 95%CI [1.89-2.77]), high histologic grade (OR=4.71, 95%CI [3.86-5.76]), negative or low hormonal receptor status (OR=1.85, 95%CI [1.67-2.04]), and higher Ki67 index (OR=3.06, 95%CI [2.72-3.44]). Bayesian Network confirmed the importance of these parameters, providing thresholds linked to high HER2 positivity rates, as shown in table below. Conclusions: HER-France is a nationwide database showing 12.0% of HER2+ on breast cancer CB between 2011 and 2015. Histological subtype, grade and ER-PR status as reported in the German database study (Ruschoff et al.), but also Ki67 are factors influencing HER2 positivity. In the future, these results should be integrated to develop new HER-France functionalities in order to allow FPL to compare their actual HER2 rate to the expected HER2 rate based on these factors.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e12089
Checking HER2 rates in breast cancer: A 4 year-experience with a nationwide database containing 105,717 records—HER-France.
E12089 Background: AFAQAP (French national quality control association in histopathology) has developed HER-France, a website tool collecting data concerning breast cancer characterization updated by pathologists. The aim of HER-France is to collect, analyze and provide consolidated data to monitor at a national and individual laboratory level the HER2 rate, and also other usual predictive and prognostic factors. It allows every participating lab to compare its own data with the national data (obtained by aggregation of data of all participating labs) to detect possible deviations from reference conditions and amend their practice if necessary. The use of HER-France is cost-free and available to all French Pathology Laboratories (FPL) on a voluntary basis since October 2011. Anonymity of the participants is protected. Roche supports AFAQAP to realize statistical analysis on HER-France database. Methods: Collected data include type of sample (core-biopsy [CB] vs lumpectomy/mastectomy), tumor type and grade, percentage of positive tumor cells for ER, PR and Ki67, mean staining intensity for ER and PR, HER2 score by immunohistochemistry (IHC) and amplification status by in situ hybridization (ISH). Results: Up to October 2015, 124 public and private FPL used HER-France and 105,717 data on specimens have been collected, among which 55,199 on CB. In order to avoid possible bias in the IHC/ISH results due to adverse pre-analytical conditions, focus was made on 45,785 untreated primitive CB of primary tumors and 2,382 metastases. The HER2 overexpression rate average since 2011 is 12.0% on primary tumors and 14.6% on metastases. Most labs that initially were outliers came gradually closer to this average. Regarding primary tumors, HER2 positivity rate was 13.5%, 4.0%, 5.0% and 0.6% for No Special Type (NST), lobular, mucinous and tubular carcinoma respectively. HER2 positivity rate for NST and lobular carcinoma was 2.8%, 11.6% and 26.6% for grade 1, 2 and 3 respectively. Conclusions: HER-France produces indicators to monitor quality of prognostic/predictive factors in breast cancer. It permits FPL to follow their own HER2 overexpression rate and compare their results to the mean national rate.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e12089
Checking HER2 rates in breast cancer: A 4 year-experience with a nationwide database containing 105,717 records—HER-France.
E12089 Background: AFAQAP (French national quality control association in histopathology) has developed HER-France, a website tool collecting data concerning breast cancer characterization updated by pathologists. The aim of HER-France is to collect, analyze and provide consolidated data to monitor at a national and individual laboratory level the HER2 rate, and also other usual predictive and prognostic factors. It allows every participating lab to compare its own data with the national data (obtained by aggregation of data of all participating labs) to detect possible deviations from reference conditions and amend their practice if necessary. The use of HER-France is cost-free and available to all French Pathology Laboratories (FPL) on a voluntary basis since October 2011. Anonymity of the participants is protected. Roche supports AFAQAP to realize statistical analysis on HER-France database. Methods: Collected data include type of sample (core-biopsy [CB] vs lumpectomy/mastectomy), tumor type and grade, percentage of positive tumor cells for ER, PR and Ki67, mean staining intensity for ER and PR, HER2 score by immunohistochemistry (IHC) and amplification status by in situ hybridization (ISH). Results: Up to October 2015, 124 public and private FPL used HER-France and 105,717 data on specimens have been collected, among which 55,199 on CB. In order to avoid possible bias in the IHC/ISH results due to adverse pre-analytical conditions, focus was made on 45,785 untreated primitive CB of primary tumors and 2,382 metastases. The HER2 overexpression rate average since 2011 is 12.0% on primary tumors and 14.6% on metastases. Most labs that initially were outliers came gradually closer to this average. Regarding primary tumors, HER2 positivity rate was 13.5%, 4.0%, 5.0% and 0.6% for No Special Type (NST), lobular, mucinous and tubular carcinoma respectively. HER2 positivity rate for NST and lobular carcinoma was 2.8%, 11.6% and 26.6% for grade 1, 2 and 3 respectively. Conclusions: HER-France produces indicators to monitor quality of prognostic/predictive factors in breast cancer. It permits FPL to follow their own HER2 overexpression rate and compare their results to the mean national rate.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e12082
Evolution of HER2 testing practices in breast cancer in France from 2005 to 2015: Results of the PartenHER national survey.
E12082 Background: For many years, French pathologists have been striving to standardize their practices and improve the quality of HER2 testing in breast cancer. The PartenHER survey aimed to assess how practices have evolved over the last decade. Methods: The PartenHER national survey is based on a questionnaire developed by a scientific committee and sent by postal mail in February 2015. Each French anatomo-cytopathology (ACP) labs received only one questionnaire. The formular was composed of 41 questions including typology of ACP labs, different technical conditions observed during pre-analytical, analytical, post-analytical steps, difficult-to-classify HER2 test results, quality controls, staff organization and training. Results: By 30 July 2015, 109 ACP labs (53% private, 47% public) regularly testing for HER2 and representing almost 620 pathologists (i.e. one third of the French pathologists) had completed the questionnaire. The study showed that in 2015, the immunohistochemistry (IHC) technique was performed by all labs, 42% of which were also performing the in situ hybridization (ISH) technique. The IHC technique was automated in 100 % of the labs, two thirds of them being automated for more than 10 years. ISH was automated in 83% of the structures and in place for more than 10 years in 20% of the cases and for five years in 56%. Several improvements in practices were also reported. Formalin is now the fixative used by 89% of labs. In 2015, 79% of the preformatted request forms were designed to collect the time of tissue removal (vs 12% in 2005), 87% were using a 3+ score reference tissue on each slide (vs 17% in 2005), 81% were tracking the HER2 overexpression rate mostly by using the HER-France national database, and 94% participated in proficiency testing, even though 42% of them had never been audited by an external authority. Conclusions: The PartenHER national survey showed that French pathologists, despite their diversity, have amended and standardized their practices regarding HER2 testing in breast cancer over the last 10 years. Further progress remains to be made, in particular to monitor the HER2 overexpression rate and resort to external audits.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e12082
Evolution of HER2 testing practices in breast cancer in France from 2005 to 2015: Results of the PartenHER national survey.
E12082 Background: For many years, French pathologists have been striving to standardize their practices and improve the quality of HER2 testing in breast cancer. The PartenHER survey aimed to assess how practices have evolved over the last decade. Methods: The PartenHER national survey is based on a questionnaire developed by a scientific committee and sent by postal mail in February 2015. Each French anatomo-cytopathology (ACP) labs received only one questionnaire. The formular was composed of 41 questions including typology of ACP labs, different technical conditions observed during pre-analytical, analytical, post-analytical steps, difficult-to-classify HER2 test results, quality controls, staff organization and training. Results: By 30 July 2015, 109 ACP labs (53% private, 47% public) regularly testing for HER2 and representing almost 620 pathologists (i.e. one third of the French pathologists) had completed the questionnaire. The study showed that in 2015, the immunohistochemistry (IHC) technique was performed by all labs, 42% of which were also performing the in situ hybridization (ISH) technique. The IHC technique was automated in 100 % of the labs, two thirds of them being automated for more than 10 years. ISH was automated in 83% of the structures and in place for more than 10 years in 20% of the cases and for five years in 56%. Several improvements in practices were also reported. Formalin is now the fixative used by 89% of labs. In 2015, 79% of the preformatted request forms were designed to collect the time of tissue removal (vs 12% in 2005), 87% were using a 3+ score reference tissue on each slide (vs 17% in 2005), 81% were tracking the HER2 overexpression rate mostly by using the HER-France national database, and 94% participated in proficiency testing, even though 42% of them had never been audited by an external authority. Conclusions: The PartenHER national survey showed that French pathologists, despite their diversity, have amended and standardized their practices regarding HER2 testing in breast cancer over the last 10 years. Further progress remains to be made, in particular to monitor the HER2 overexpression rate and resort to external audits.
- Open Access
- 19 May 2015
- Published by Springer Nature in Virchows Archiv
- Vol. 467 (2) , 169-175
HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide
Human epidermal growth factor receptor 2 (HER2) status in breast carcinomas serves as a predictor of benefit from anti-HER2 therapy. In providing clinicians with the information necessary to decide whether or not to treat with targeted therapy, it might be necessary to choose between methods assessing HER2 protein overexpression or gene amplification. A new diagnostic approach could be a combination of both tests on the same slide. If accurate and reproducible, this approach might optimize patient stratification for therapy. In this study, formalin-fixed paraffin-embedded tumor samples from 77 breast cancer patients were examined for HER2 by immunohistochemistry (IHC) and silver in situ hybridization (SISH) using HER2 IHC (clone 4B5), HER2/CEN17SISH, and combined IHC and SISH assay, called gene protein (GP). Cases were selected to ensure a sufficient number of borderline cases on the basis of IHC scores (0, 1+, 2+, 3+), obtained during diagnostic histopathological workup. The concordance between the HER2 IHC score obtained during diagnostic histopathological workup and GP was 93 %. Discordances had no influence on therapy decisions. The concordance between ISH results using dual ISH (DISH) and GP was 96 %. Of the 77 cases studied by GP, three cases with a ratio close to 2 would have been called amplified by DISH. The use of GP reduced the time for slide reading for a trained pathologist by up to 25 %, relative to sequential reading of IHC followed by SISH. For cases with an IHC score of 2+, the final result was obtained in 1 day, while the sequential technique would have required retesting by ISH on a second day. In conclusion, assessment of HER2 status by GP is an improvement for pathologists and facilitates clinical decision-making for breast cancer management.
- 19 May 2015
- Published by Springer Nature in Virchows Archiv
- Vol. 467 (2) , 169-175
Open AccessHER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide
Human epidermal growth factor receptor 2 (HER2) status in breast carcinomas serves as a predictor of benefit from anti-HER2 therapy. In providing clinicians with the information necessary to decide whether or not to treat with targeted therapy, it might be necessary to choose between methods assessing HER2 protein overexpression or gene amplification. A new diagnostic approach could be a combination of both tests on the same slide. If accurate and reproducible, this approach might optimize patient stratification for therapy. In this study, formalin-fixed paraffin-embedded tumor samples from 77 breast cancer patients were examined for HER2 by immunohistochemistry (IHC) and silver in situ hybridization (SISH) using HER2 IHC (clone 4B5), HER2/CEN17SISH, and combined IHC and SISH assay, called gene protein (GP). Cases were selected to ensure a sufficient number of borderline cases on the basis of IHC scores (0, 1+, 2+, 3+), obtained during diagnostic histopathological workup. The concordance between the HER2 IHC score obtained during diagnostic histopathological workup and GP was 93 %. Discordances had no influence on therapy decisions. The concordance between ISH results using dual ISH (DISH) and GP was 96 %. Of the 77 cases studied by GP, three cases with a ratio close to 2 would have been called amplified by DISH. The use of GP reduced the time for slide reading for a trained pathologist by up to 25 %, relative to sequential reading of IHC followed by SISH. For cases with an IHC score of 2+, the final result was obtained in 1 day, while the sequential technique would have required retesting by ISH on a second day. In conclusion, assessment of HER2 status by GP is an improvement for pathologists and facilitates clinical decision-making for breast cancer management.
- Open Access
- 10 October 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 268
First report of granulomatous mastitis associated with Sjögren’s syndrome
Granulomatous mastitis is a rare and often considered as idiopathic disease. However, clinical examination and thorough diagnostic investigations have to be carried out in order to identify cases that are secondary to infections or systemic diseases since these forms may be cured with appropriate etiologic treatment. To the best of our knowledge, this report is the first to describe the association of granulomatous mastitis with Sjögren’s syndrome. We discuss the clinical, pathological and therapeutic implications of this association.
- 10 October 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 268
Open AccessFirst report of granulomatous mastitis associated with Sjögren’s syndrome
Granulomatous mastitis is a rare and often considered as idiopathic disease. However, clinical examination and thorough diagnostic investigations have to be carried out in order to identify cases that are secondary to infections or systemic diseases since these forms may be cured with appropriate etiologic treatment. To the best of our knowledge, this report is the first to describe the association of granulomatous mastitis with Sjögren’s syndrome. We discuss the clinical, pathological and therapeutic implications of this association.
- 1 November 2012
- Published by Elsevier in Annales de Pathologie
- Vol. 32 (5) , S94-S95
ICC et IHC : technique et assurance qualité. Conclusions tirées des tests de l’AFAQAP en IHC
- 1 November 2012
- Published by Elsevier in Annales de Pathologie
- Vol. 32 (5) , S94-S95
ICC et IHC : technique et assurance qualité. Conclusions tirées des tests de l’AFAQAP en IHC
- 1 November 2012
- Published by Elsevier in Annales de Pathologie
- Vol. 32 (5) , S80-S81
La 15189 en ACP : 1515, 1789 ou 14-18 ? Informations et propositions pour avancer sans se prendre la tête
- 1 November 2012
- Published by Elsevier in Annales de Pathologie
- Vol. 32 (5) , S80-S81
La 15189 en ACP : 1515, 1789 ou 14-18 ? Informations et propositions pour avancer sans se prendre la tête
- Open Access
- 3 November 2011
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 132 (3) , 895-915
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
Clinicians can use biomarkers to guide therapeutic decisions in estrogen receptor positive (ER+) breast cancer. One such biomarker is cellular proliferation as evaluated by Ki-67. This biomarker has been extensively studied and is easily assayed by histopathologists but it is not currently accepted as a standard. This review focuses on its prognostic and predictive value, and on methodological considerations for its measurement and the cut-points used for treatment decision. Data describing study design, patients’ characteristics, methods used and results were extracted from papers published between January 1990 and July 2010. In addition, the studies were assessed using the REMARK tool. Ki-67 is an independent prognostic factor for disease-free survival (HR 1.05–1.72) in multivariate analyses studies using samples from randomized clinical trials with secondary central analysis of the biomarker. The level of evidence (LOE) was judged to be I-B with the recently revised definition of Simon. However, standardization of the techniques and scoring methods are needed for the integration of this biomarker in everyday practice. Ki-67 was not found to be predictive for long-term follow-up after chemotherapy. Nevertheless, high KI-67 was found to be associated with immediate pathological complete response in the neoadjuvant setting, with an LOE of II-B. The REMARK score improved over time (with a range of 6–13/20 vs. 10–18/20, before and after 2005, respectively). KI-67 could be considered as a prognostic biomarker for therapeutic decision. It is assessed with a simple assay that could be standardized. However, international guidelines are needed for routine clinical use.
- 3 November 2011
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 132 (3) , 895-915
Open AccessKi-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
Clinicians can use biomarkers to guide therapeutic decisions in estrogen receptor positive (ER+) breast cancer. One such biomarker is cellular proliferation as evaluated by Ki-67. This biomarker has been extensively studied and is easily assayed by histopathologists but it is not currently accepted as a standard. This review focuses on its prognostic and predictive value, and on methodological considerations for its measurement and the cut-points used for treatment decision. Data describing study design, patients’ characteristics, methods used and results were extracted from papers published between January 1990 and July 2010. In addition, the studies were assessed using the REMARK tool. Ki-67 is an independent prognostic factor for disease-free survival (HR 1.05–1.72) in multivariate analyses studies using samples from randomized clinical trials with secondary central analysis of the biomarker. The level of evidence (LOE) was judged to be I-B with the recently revised definition of Simon. However, standardization of the techniques and scoring methods are needed for the integration of this biomarker in everyday practice. Ki-67 was not found to be predictive for long-term follow-up after chemotherapy. Nevertheless, high KI-67 was found to be associated with immediate pathological complete response in the neoadjuvant setting, with an LOE of II-B. The REMARK score improved over time (with a range of 6–13/20 vs. 10–18/20, before and after 2005, respectively). KI-67 could be considered as a prognostic biomarker for therapeutic decision. It is assessed with a simple assay that could be standardized. However, international guidelines are needed for routine clinical use.